SweetValueLab
Write for us

Agilent Technologies, Inc. — Wall Street Analyst Estimates & Price Targets

A
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001090872agilent.comAbout A
Last close · Oct 16, 2026172.97−2.58 (−1.47%)
Market cap$48.8B

10 firms' latest targets, last 90 days: median $180.00 ($155.00–$195.00), 4% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$150$200$250NovJan 2026MarMayJulSep2025-11-25 · Stifel: $1702025-11-25 · UBS: $1802025-11-25 · Baird: $1652025-11-25 · Barclays: $1652025-11-25 · Wells Fargo: $1652025-12-01 · Morgan Stanley: $2702025-12-02 · Morgan Stanley: $1802025-12-09 · Goldman Sachs: $1702026-01-05 · Evercore ISI: $1602026-01-20 · HSBC: $1802026-03-09 · Fermium Research: $1502026-04-14 · Barclays: $1402026-05-26 · RBC Capital: $1532026-05-26 · Baird: $1562026-05-28 · RBC Capital: $1552026-05-28 · Baird: $1582026-05-28 · Wells Fargo: $1602026-06-03 · HSBC: $1652026-06-11 · Piper Sandler: $1502026-07-06 · Evercore ISI: $1482026-08-27 · Wells Fargo: $1802026-08-27 · Barclays: $1752026-08-27 · RBC Capital: $1852026-08-27 · RBC Capital: $1802026-08-27 · Evercore ISI: $1722026-08-27 · Bernstein: $1802026-08-27 · Goldman Sachs: $1752026-08-27 · Stifel: $1802026-09-02 · Jefferies: $1552026-09-09 · UBS: $1652026-10-07 · Barclays: $1952026-10-12 · Morgan Stanley: $190
$150$200$250NovFebMayAug

Each firm's latest target

last 90 days · 10 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-12Morgan Stanley$190.00$180.00▲ 6%+11%+10%
2026-10-07Barclays$195.00$175.00▲ 11%+15%+13%
2026-09-09UBS$165.00$180.00▼ 8%+12%-5%
2026-09-02Jefferies$155.00——+2%-10%
2026-08-27Wells Fargo$180.00$160.00▲ 13%+14%+4%
2026-08-27RBC Capital$185.00$180.00▲ 3%+17%+7%
2026-08-27Evercore ISI$172.00$148.00▲ 16%+11%-1%
2026-08-27Bernstein$180.00——+16%+4%
2026-08-27Goldman Sachs$175.00$170.00▲ 3%+13%+1%
2026-08-27Stifel$180.00$170.00▲ 6%+16%+4%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$6.8B+0%$4.19+0%est. $6.8B+0%est. $5.4111
2024reported$6.5B-5%$4.43+6%est. $6.5B+0%est. $5.2417
2025reported$6.9B+7%$4.57+3%est. $6.9B+0%est. $5.5710
2026$7.5B+8%$6.20+11%$7.5B–$7.5B$6.19–$6.2915
2027$8.0B+6%$6.74+9%$7.9B–$8.0B$6.51–$6.9715
2028$8.5B+7%$7.44+10%$8.3B–$8.8B$6.92–$8.0017
2029$9.1B+7%$8.26+11%$9.0B–$9.2B$8.15–$8.378
2030$9.4B+3%$9.00+9%$9.2B–$9.5B$8.89–$9.138
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.